In a report published Monday, H.C. Wainwright & Co. analyst Andrew S. Fein initiated coverage on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a Buy rating and $21.00 price target.
In the report, H.C. Wainwright & Co. noted, “Biocryst's...
Analysts at UBS initiated coverage on shares of Concert Pharmaceuticals (NASDAQ: CNCE) with a “buy” rating. The target price for Concert Pharma is set to $25. Concert Pharma's shares closed at $14.88 on Friday.
HC Wainwright initiated...
By Markus Aarnio:
BioCryst Pharmaceuticals (BCRX) designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases.
(click to enlarge)
Insider selling during the last 30 days
Here is a table...
BioCryst Pharmaceuticals, Inc. (BCRX)
Q4 2013 Earnings Conference Call
February 26, 2014 11:00 a.m. ET
Robert Bennett – VP, IR
Jon Stonehouse – President and CEO
Thomas Staab – SVP and CFO
zulily (NASDAQ: ZU) soared 10.81% to $47.47 in the pre-market trading after the company reported upbeat Q4 results.
Cara Therapeutics (NASDAQ: CARA) surged 10.34% to $16.00 in the pre-market session after Stifel Nicolaus initiated coverage on...
Analysts at Jefferies downgraded First Niagara Financial Group (NASDAQ: FNFG) from “outperform” to “hold.” The target price for First Niagara Financial Group has been raised from $12 to $19. First Niagara Financial's shares closed at $9.08...
Analysts at ISI Group initiated coverage on shares of Intuitive Surgical (NASDAQ: ISRG) with a “strong buy” rating. The target price for Intuitive Surgical is set to $50. Intuitive Surgical's shares closed at $430.14 on Friday.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.